- Home
- SHOO vs TARS Comparison
SHOO vs TARS Comparison
Compare SHOO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOO | TARS |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SHOO | TARS |
|---|---|---|
| Price | $36.53 | $65.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $42.75 | ★ $77.13 |
| AVG Volume (30 Days) | ★ 1.6M | 536.5K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $2,362,727,000.00 | $366,100,000.00 |
| Revenue This Year | $13.06 | $147.71 |
| Revenue Next Year | $12.67 | $53.74 |
| P/E Ratio | $45.72 | ★ N/A |
| Revenue Growth | 6.41 | ★ 182.44 |
| 52 Week Low | $19.05 | $38.51 |
| 52 Week High | $46.88 | $85.25 |
Technical Indicators
Market Signals| Indicator | SHOO | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 37.43 |
| Support Level | $33.89 | $61.67 |
| Resistance Level | $46.88 | $67.45 |
| Average True Range (ATR) | 2.13 | 3.13 |
| MACD | -1.16 | -0.14 |
| Stochastic Oscillator | 20.63 | 30.00 |
Price Performance
Historical ComparisonAbout SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.